Prognostic role of pre-treatment serum AFP-L3% in hepatocellular carcinoma: Systematic review and meta-analysis

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Cheng, Jiwen ^a   Wang, Wanli ^a,b   Zhang, Yingjun ^b   Liu, Xi ^c   Li, Muxing ^a   Wu, Zheng ^a   Liu, Zhengwen ^a   Lv, Yi ^a   Wang, Bo ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b Central Hospital of Bazhong   (China)

^c First Affiliated Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CHEMOEMBOLIZATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; QUALITY CONTROL; RADIOFREQUENCY ABLATION; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; BLOOD; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; METABOLISM; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; HUMANS; LIVER NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 84900429823     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087011     Document Type: Article

References (37)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30.
2. Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, et al. (2004) A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 130: 187-196.
3. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35: 421-430. (Pubitemid 32844200)
4. Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379: 1245-1255.
5. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, et al. (2001) Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 91: 561-569. (Pubitemid 32105702)
6. Song BC, Suh DJ, Yang SH, Lee HC, Chung YH, et al. (2002) Lens culinaris agglutinin-reactive alpha-fetoprotein as a prognostic marker in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization. J Clin Gastroenterol 35: 398-402. (Pubitemid 35278662)
7. Zhang XF, Lai EC, Kang XY, Qian HH, Zhou YM, et al. (2011) Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and a monitor of recurrence of hepatocellular carcinoma after curative liver resection. Ann Surg Oncol 18: 2218-2223.
8. Saito Y, Shimada M, Utsunomiya T, Morine Y, Imura S, et al. (2012) Prediction of recurrence of hepatocellular carcinoma after curative hepatectomy using preoperative Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein. Hepatol Res 42: 887-894.
9. Kobayashi M, Kuroiwa T, Suda T, Tamura Y, Kawai H, et al. (2007) Fucosylated fraction of alpha-fetoprotein, L3, as a useful prognostic factor in patients with hepatocellular carcinoma with special reference to low concentrations of serum alpha-fetoprotein. Hepatol Res 37: 914-922. (Pubitemid 47399920)
10. Beppu T, Sugimoto K, Shiraki K, Tameda M, Kusagawa S, et al. (2010) Clinical significance of tumor markers in detection of recurrent hepatocellular carcinoma after radiofrequency ablation. Int J Mol Med 26: 425-433.
11. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, et al.(1999) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available: http://www.ohri.ca/programs/clinical-epidemiology/ oxford-web.ppt. Accessed 26 May 2013.
12. Reeves BC, Higgins J, Ramsay C, Shea B, Tugwell P, et al. (2013) An introduction to methodological issues when including non-randomised studies in systematic reviews on the effects of interventions. Res Syn Meth 4: 1-11.
13. Liu J, Ma Q, Zhang M, Wang X, Zhang D, et al. (2012) Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis. Eur J Cancer 48: 2328-2338.
14. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-2834. (Pubitemid 28562978)
15. Thompson SG, Higgins JP (2002) How should meta-regression analyses be undertaken and interpreted? Stat Med 21: 1559-1573. (Pubitemid 34746063)
16. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634. (Pubitemid 27387172)
17. Takeji S, Hirooka M, Koizumi Y, Tokumoto Y, Abe M, et al. (2013) Des-gamma-carboxy prothrombin identified by P-11 and P-16 antibodies reflects prognosis for patients with hepatocellular carcinoma. J Gastroenterol Hepatol 28: 671-677.
18. Kobayashi M, Hosaka T, Ikeda K, Seko Y, Kawamura Y, et al. (2011) Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively. Hepatol Res 41: 1036-1045.
19. Nouso K, Kobayashi Y, Nakamura S, Kobayashi S, Takayama H, et al. (2011) Prognostic importance of fucosylated alpha-fetoprotein in hepatocellular carcinoma patients with low alpha-fetoprotein. J Gastroenterol Hepatol 26: 1195-1200.
20. Toyoda H, Kumada T, Tada T, Niinomi T, Ito T, et al. (2012) Prognostic significance of a combination of pre- and post-treatment tumor markers for hepatocellular carcinoma curatively treated with hepatectomy. J Hepatol 57: 1251-1257.
21. Toyoda H, Kumada T, Kaneoka Y, Osaki Y, Kimura T, et al. (2008) Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. J Hepatol 49: 223-232.
22. Fukuda H (1998) Tumor vascularity and lens culinaris agglutinin reactive alpha-fetoprotein are predictors of long-term prognosis in patients with hepatocellular carcinoma after percutaneous ethanol injection therapy. Kurume Med J 45: 187-193.
23. Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, et al. (2012) Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 107: 569-577; quiz 578.
24. Shiozawa K, Watanabe M, Wakui N, Ikehara T, Iida K, et al. (2009) Risk factors for the local recurrence of hepatocellular carcinoma after single-session percutaneous radiofrequency ablation with a single electrode insertion. Mol Med Rep 2: 89-95.
25. Leerapun A, Suravarapu SV, Bida JP, Clark RJ, Sanders EL, et al. (2007) The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population. Clin Gastroenterol Hepatol 5: 394-402; quiz 267.
26. Tamura Y, Igarashi M, Kawai H, Suda T, Satomura S, et al. (2010) Clinical advantage of highly sensitive on-chip immunoassay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma. Dig Dis Sci 55: 3576-3583.
27. Tung-Ping Poon R, Fan ST, Wong J (2000) Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 232: 10-24.
28. Yamashita F, Tanaka M, Satomura S, Tanikawa K (1996) Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas. Gastroenterology 111: 996-1001. (Pubitemid 26327602)
29. Aoyagi Y, Isokawa O, Suda T, Watanabe M, Suzuki Y, et al. (1998) The fucosylation index of alpha-fetoprotein as a possible prognostic indicator for patients with hepatocellular carcinoma. Cancer 83: 2076-2082. (Pubitemid 28525388)
30. Hayashi K, Kumada T, Nakano S, Takeda I, Sugiyama K, et al. (1999) Usefulness of measurement of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma. Am J Gastroenterol 94: 3028-3033. (Pubitemid 29482777)
31. Oka H, Saito A, Ito K, Kumada T, Satomura S, et al. (2001) Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein. J Gastroenterol Hepatol 16: 1378-1383. (Pubitemid 34107406)
32. Tateishi R, Shiina S, Yoshida H, Teratani T, Obi S, et al. (2006) Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology 44: 1518-1527. (Pubitemid 44953657)
33. Miyaaki H, Nakashima O, Kurogi M, Eguchi K, Kojiro M (2007) Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma. J Gastroenterol 42: 962-968.
34. Kawabata T, Wada HG, Watanabe M, Satomura S (2008) Electrokinetic analyte transport assay for alpha-fetoprotein immunoassay integrates mixing, reaction and separation on-chip. Electrophoresis 29: 1399-1406. (Pubitemid 351524351)
35. Kagebayashi C, Yamaguchi I, Akinaga A, Kitano H, Yokoyama K, et al. (2009) Automated immunoassay system for AFP-L3% using on-chip electrokinetic reaction and separation by affinity electrophoresis. Anal Biochem 388: 306-311.
36. Fujiyama S, Tanaka M, Maeda S, Ashihara H, Hirata R, et al. (2002) Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 62 Suppl 1: 57-63. (Pubitemid 34702021)
37. Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, et al. (2006) Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 4: 111-117. (Pubitemid 43129532)